

## Lexaria's Technology Now Works in Less Than 10 Minutes

**Kelowna, British Columbia– November 21, 2019** – Lexaria Bioscience Corp. (OTCQX: LXP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has developed additional enhancements for its industry-leading DehydraTECH™ platform that delivers THC onset of action in human pilot testing in less than 10 minutes.

In recent human subjective pilot tests, volunteers reported onset of THC action from edibles formulated with this latest DehydraTECH innovation in less than 10 minutes. This enhanced version is roughly twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations.

Oral delivery of THC within 10 minutes offers significant advantages for both medical and adult use applications where rapid onset is highly desirable in response to certain conditions such as pain or seizures. Generic cannabis edibles often require 90 to 120 minutes after ingestion before there are perceptible effects of THC.

DehydraTECH has been delivering consistent benefits to consumers of cannabis edibles for three years with rapid delivery, superior pharmacokinetics, and elevated consumer experiences. Consumers of edibles processed with traditional DehydraTECH are among the industry's most loyal customers because of consistent and rapid delivery of cannabis experiences.

On June 4, 2019, Lexaria announced that DehydraTECH innovations demonstrated through a series of animal studies an ability to deliver 811% more CBD into blood; and up to 1,937% more into brain tissue, both compared to generic industry MCT formulations.

Lexaria's latest discovery represents an additional DehydraTECH innovation and expands the use of enhanced DehydraTECH in that the new evaluation was completed with human volunteers and was conducted with THC rather than with CBD as was used in the earlier animal studies.

Additional testing and evaluation will be required before the latest DehydraTECH improvements will be released to Lexaria technology licensees, which is expected near Q2 of 2020. Lexaria is committed to an ongoing program of continual improvements in drug delivery.

### **About Lexaria**

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a world-leading tobacco

producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

[www.lexariabioscience.com](http://www.lexariabioscience.com)



For regular updates, connect with Lexaria on Twitter (<https://twitter.com/lexariacorp>)



and on Facebook <https://www.facebook.com/lexariabioscience/>

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.

Alex Blanchard, Communications Manager

(250) 765-6424 ext. 202

Or

NetworkNewsWire (NNW)

[www.NetworkNewsWire.com](http://www.NetworkNewsWire.com)

#### FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No



statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

*The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*